Last reviewed · How we verify
cyclo phosphamide
Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and causing cancer cell death.
Cyclophosphamide, an alkylating agent, is used in various hematological malignancies and autoimmune disorders. It is being evaluated in multiple clinical trials, including CAR T-cell therapy and stem cell transplantation. Despite no FDA label, it has off-label uses in lupus nephritis and multiple sclerosis.
At a glance
| Generic name | cyclo phosphamide |
|---|---|
| Sponsor | Al-Azhar University |
| Drug class | Alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | FDA-approved |
Mechanism of action
Cyclophosphamide is a nitrogen mustard derivative that requires hepatic activation to form active metabolites. These metabolites covalently bind to DNA, creating inter- and intra-strand cross-links that inhibit DNA replication and transcription, leading to apoptosis. It is also immunosuppressive, depleting lymphocytes and suppressing antibody production.
Approved indications
- Lymphomas (Hodgkin and non-Hodgkin)
- Leukemias (acute and chronic)
- Multiple myeloma
- Breast cancer
- Ovarian cancer
- Severe autoimmune diseases (systemic lupus erythematosus, vasculitis)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Alopecia
- Hemorrhagic cystitis
- Infertility
- Secondary malignancies
- Immunosuppression and infection risk
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cyclo phosphamide CI brief — competitive landscape report
- cyclo phosphamide updates RSS · CI watch RSS
- Al-Azhar University portfolio CI